A E van der Meulen-de Jong

Publications (3)28.21 Total impact

• Article: High detection rate of adenomas in familial colorectal cancer.

  A E van der Meulen-de Jong, H Morreau, M C J M Becx, L F S J Crobach, M van Haastert, W R ten Hove, J H Kleibeuker, M A C Meijssen, F M Nagengast, M C M Rijk, [......], H A R E Tuynman, J Vecht, M L Verhulst, W H de Vos tot Nederveen Cappel, H Walinga, O K Weinhardt, B D Westerveld, A M C Witte, H J Wolters, H F A Vasen
  [show abstract] [hide abstract]
  ABSTRACT: Subjects with one first-degree relative (FDR) with colorectal cancer (CRC) <50 years old or two FDRs with CRC have an increased risk for CRC (RR 4-6). Current guidelines recommend colonoscopic surveillance of such families. However, information about the yield of surveillance is limited. The aim of the present study was to evaluate the outcome of surveillance and to identify risk factors for the development of adenomas. Subjects were included if they fulfilled the following criteria: asymptomatic subjects aged between 45 and 65 years, with one FDR with CRC <50 years old (group A) or two FDRs with CRC diagnosed at any age (group B). Subjects with a personal history of inflammatory bowel disease or colorectal surgery were excluded. A total of 551 subjects (242 male) met the selection criteria. Ninety-five subjects with a previous colonoscopy were excluded. Two of 456 remaining subjects (0.4%) were found to have a colorectal tumour (one CRC and one carcinoid). Adenomas were detected in 85 (18.6%) and adenomas with advanced pathology in 37 subjects (8.1%). 30 subjects (6.6%) had multiple (>1) adenomas. Men were more often found to have an adenoma than women (24% vs 14.3%; p=0.01). Adenomas were more frequent in group B compared with group A (22.0% vs 15.6%; p=0.09). The yield of colonoscopic surveillance in familial CRC is substantially higher than the yield of screening reported for the general population.
  Gut 01/2011; 60(1):73-6. · 10.11 Impact Factor
• Article: One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

  Hans F A Vasen, Mohamed Abdirahman, Richard Brohet, Alexandra M J Langers, Jan H Kleibeuker, Mariette van Kouwen, Jan Jacob Koornstra, Henk Boot, Annemieke Cats, Evelien Dekker, [......], Maarten A J M Jacobs, Faig Lall A Mohamed, Sijbrand Y de Boer, Paul C van de Meeberg, Marie-Louise Verhulst, Jan M Salemans, Nico van Bentem, B Dik Westerveld, Juda Vecht, Fokko M Nagengast
  [show abstract] [hide abstract]
  ABSTRACT: Two percent to 4% of all cases of colorectal cancer (CRC) are associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) accounts for 1%-3% of the cases. Because carcinogenesis is accelerated in Lynch syndrome, an intensive colonoscopic surveillance program has been recommended since 1995. The aim of the study was to evaluate the effectiveness of this program. The study included 205 Lynch syndrome families with identified mutations in one of the mismatch repair genes (745 mutation carriers). We also analyzed data from non-Lynch syndrome families (46 families, 344 relatives). Patients were observed from January 1, 1995, until January 1, 2009. End points of the study were CRC or date of the last colonoscopy. After a mean follow-up of 7.2 years, 33 patients developed CRC under surveillance. The cumulative risk of CRC was 6% after the 10-year follow-up period. The risk of CRC was higher in carriers older than 40 years and in carriers of MLH1 and MSH2 mutations. After a mean follow-up of 7.0 years, 6 cases of CRC were detected among non-Lynch syndrome families. The risk of CRC was significantly higher among families with Lynch syndrome, compared with those without. With surveillance intervals of 1-2 years, members of families with Lynch syndrome have a lower risk of developing CRC than with surveillance intervals of 2-3 years. Because of the low risk of CRC in non-Lynch syndrome families, a less intensive surveillance protocol can be recommended.
  Gastroenterology 03/2010; 138(7):2300-6. · 11.68 Impact Factor
• Article: Familial colorectal cancer risk: ESMO clinical recommendations.

  H F A Vasen, A E van der Meulen-de Jong, W H de Vos Tot Nederveen Cappel, J Oliveira
  Annals of Oncology 05/2009; 20 Suppl 4:51-3. · 6.43 Impact Factor